J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics ‘JIN-A02’ and ‘JIN-001’ at AACR 2025
Hand-out
Press Releases
May 1, 2025

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics ‘JIN-A02’ and ‘JIN-001’ at AACR 2025

SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings for the next-generation EGFR-TKI therapeutic 'JIN-A02' (clinical

bradford

The Bradford Era

Local & Social